Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya(r) for the Treatment of Posttraumatic Stress Disorder

MLA

“Tonix Pharmaceuticals Announces That Breakthrough Therapy Designation Remains in Effect for Tonmya(r) for the Treatment of Posttraumatic Stress Disorder.” Plus Company Updates, 23 Apr. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.583415422&authtype=sso&custid=ns315887.

APA

Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya(r) for the Treatment of Posttraumatic Stress Disorder. (2019, April 23). Plus Company Updates.

Chicago

Plus Company Updates. 2019. “Tonix Pharmaceuticals Announces That Breakthrough Therapy Designation Remains in Effect for Tonmya(r) for the Treatment of Posttraumatic Stress Disorder,” April 23. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.583415422&authtype=sso&custid=ns315887.